CA153在乳腺癌免疫治疗中的作用

doi:10.11904/j.issn.1002-3070.2019.06.018

摘要/Abstract

摘要： 乳腺癌是女性常见的恶性肿瘤,免疫治疗是临床上取得较好效果的治疗手段之一。CA153可在乳腺癌免疫应答中作为特异性抗原激活免疫应答;参与T细胞活化;靶向结合多肽疫苗,增强免疫应答;诱导树突状细胞成熟,清除体内癌细胞等。因此CA153在乳腺癌的免疫应答和治疗中具有重要的作用,可作为乳腺癌免疫治疗的新靶点。

关键词: CA153, 乳腺癌, 免疫治疗, 靶点

Abstract: Breast cancer is a common malignant tumor in women,and immunotherapy is one of the treatments with a good clinical prognosis.CA153 can activate immune response as a specific antigen in breast cancer immune response;participate in T cell activation;target binding peptide vaccine;enhance immune response;induce dendritic cell maturation,and eliminate cancer cells in vivo.Therefore,CA153 plays an important role in the immune response and treatment of breast cancer,and can be used as a new target for breast cancer immunotherapy.

Key words: CA153, Breast cancer, Immunotherapy, Target

中图分类号:

R730.4

曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.

CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy[J]. Journal of Practical Oncology, 2019, 33(6): 566-569.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.06.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I6/566

参考文献

1 钱六七,刘芊,刘毅,等.循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系[J].实用肿瘤学杂志,2012,26(3):220-224.
2 Van Dalen A,Favier J,Baumgartner L,et al.Serum levels of CA 125 and TPS during treatment of ovarian cancer[J].Anticancer Res,2000,20(6):5107-5108.
3 Pan D,Chen J,Feng C,et al.Preferential localization of MUC1 glycoproteinin exosomes secreted by non-small cell lung carcinoma cells[J].Int J Mol Sci,2019,14(2):323.
4 Li X,Bleumink-Pluym NMC,Luijkx YMCA,et al.MUC1 is a receptor for the Salmonella SiiE adhesin that enables apical invasion into enterocytes[J].PLoS Pathog,2019,15(2):e1007566.
5 Apostolopoulos V,Stojanovska L,Gargosky SE,et al.MUC1(CD227):a multi-tasked molecule:CMLS[J].Cell Mol Life Sci,2015,72(23):4475-4500.
6 Song W,Delyria ES,Chen J,et al.MUC1 glycopeptide epitopes predictedby computational glycomics[J].Int J Oncol,2012,41(6):1977-1984.
7 Nath S,Mukherjee P.MUC1:a multifaceted oncoprotein with a key role in cancer progression[J].Trends Mol Med,2014,20(6):332-342.
8 Dhar P,Ng GZ,Dunne EM,et al.Mucin 1 protects against severe streptococcus pneumoniae infection[J].Virulence,2017,8(8):1631-1642.
9 Jing X,Liang H,Hao C,et al.Overexpression of MUC1 predicts poor prognosis in patients with breast cancer[J].Oncol Rep,2019,41(2):801-810.
10 Posey A,Schwab R,Boesteanu A,et al.Engineered CAR T cells targeting the cancer-associated tnglycoform of the membrane mucin MUC1 control ade-nocarcinoma[J].Immunity,2016,44(6):1444-1454.
11 Hillman GG,Reich LA,Rothstein SE,et al.Radiotherapy and MVA-MUC1-IL-2vaccine act synergistically for inducing specific immunity to MUC-1 tumorantigen[J].J Immunother Cancer,2017,5:4.
12 Takeshima T,Chamoto K,Wakita D,et al.Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL:its potentiation by combination with Th1 cell therapy[J].Cancer Res,2010,70(7):2697-2706.
13 Kimura T,McKolanis JR,Dzubinski LA,et al.MUC1 vaccine for individual with advanced adenoma of the colon:a cancer immunoprevention feasibility study[J].Cancer Prev Res,2013,6(1):18-26.
14 Hanafi-Bojd MY,Moosavian Kalat SA,Taghdisi SM,et al.MUC1 aptamer conjugated mesoporous silica nanoparticles effectively target breast cancer cells[J].Drug Dev Ind Pharm,2018,44(1):13-18.
15 Limacher JM,Quoix E.TG4010:A therapeutic vaccine against MUC1 expressing tumors[J].Oncoimmunology,2012,1(5):791-792.
16 Taylor-Papadimitriou J,Burchell JM,Graham R,et al.Latest developments in MUC1 immunotherapy[J].Biochem Soc T,2018,46(3):659-668.
17 Ahmad R,Alam M,Rajabi H,et al.The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function[J].JBC,2012,287(25):20866-20875.
18 Nabavinia MS,Gholoobi A,Charbgoo F,et al.Anti-MUC1 aptamer:a potential opportunity for cancer treatment[J].Med Res Rev,2017,37(6):1518-1539.
19 Zhou R,Yazdanifar M,Roy LD,et al.CAR T cells targeting the tumor MUC1 glycoprotein reduce triple negative Breast Cancer growth[J].Front Immunol,2019,24(10):1149.
20 Madsen CB,Wandal HH,Pedersen AE.Potential for novel MUC1 glycopeptide specific antibody in passive cancer immunotherapy[J].Immunopharmacol Immunotoxicol,2013,35(6):649-652.
21 Zhou D,Xu L,Huang W,et al.Epitopes of MUC1 tandem repeats in cancer as revealed by antibody crystallography:toward glycopeptide signature-guided therapy[J].Molecules,2018,23(6):1326.
22 Wang Y,Liu C,Xia Q,et al.Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs[J].Oncol Rep,2014,31(3):1437-1444.
23 Movahedin M,Brooks TM,Supekar NT,et al.Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen[J].Glycobiology,2017,27(7):677-687.
24 Lakshminarayanan V,Supekar NT,Wei J,et al.MUC1 vaccines comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1 can circumvent immunoediting to control tumor growth in MUC1 transgenic mice[J].PLoS One,2016,11(1):e0145920.
25 Vasir B,Zarwan C,Ahmad R,et al.Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1,CEA,and a triad of costimulatory molecules(rF-PANVAC)[J].J Immunother,2012,35(7):555-569.
26 Schettini J,Kidiyoor A,Besmer DM,et al.Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity[J].Cancer Immunology Immunotherapy,2012,61(11):2055-2065.
27 Alves LN,Missailidis S,Lage CAS,et al.Anti-MUC1 aptamer as carrier tool of the potential radiosensitizer 10 phenanthroline in MCF-7 Breast Cancer cells[J].Anticancer Res,2019,39(4):1859-1867.
28 Pillai K,Pourgholami MH,Chua TC,et al.MUC1 as a potential target in anticancer therapies[J].Am J Clin Oncol,2015,38:108-118.

[1]	沈依哲, 郭宝良. 初诊Ⅳ期乳腺癌的局部治疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 575-578.
[2]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[3]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.
[4]	王宇, 乔娟娟, 张磊, 刘四卫 , 杨树才. 类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 466-470.
[5]	刘尔钰, 杨昊, 梁国华, 赵晏方, 赵文辉. CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制[J]. 实用肿瘤学杂志, 2019, 33(5): 476-480.
[6]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[7]	胡琳, 沈佳. GDF-15在预测和监控表柔比星/环磷酰胺-多西他赛-曲妥珠单抗辅助治疗HER-2阳性乳腺癌患者产生心脏毒性中的作用[J]. 实用肿瘤学杂志, 2019, 33(4): 340-345.
[8]	马焱, 何红, 王赛男. 多西他赛解救治疗不同年龄组转移性乳腺癌的临床研究[J]. 实用肿瘤学杂志, 2019, 33(4): 352-356.
[9]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[10]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[11]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[12]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[13]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[14]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[15]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.